Overview

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Status:
Unknown status

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects

Phase:

Phase 2

Details

Lead Sponsor:

Armando Santoro, MD

Treatments:

Bendamustine Hydrochloride
Gemcitabine
Vinblastine
Vinorelbine